Auxier Asset Management Sells 2,816 Shares of Kenvue Inc. (NYSE:KVUE)

Auxier Asset Management lessened its holdings in shares of Kenvue Inc. (NYSE:KVUE) by 10.3% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 24,541 shares of the company’s stock after selling 2,816 shares during the quarter. Auxier Asset Management’s holdings in Kenvue were worth $446,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Manchester Capital Management LLC lifted its stake in shares of Kenvue by 80.8% during the 1st quarter. Manchester Capital Management LLC now owns 1,186 shares of the company’s stock worth $25,000 after buying an additional 530 shares during the last quarter. Mather Group LLC. acquired a new stake in Kenvue during the first quarter worth approximately $28,000. Riverview Trust Co bought a new stake in shares of Kenvue during the first quarter worth approximately $33,000. MV Capital Management Inc. boosted its holdings in shares of Kenvue by 71.2% during the first quarter. MV Capital Management Inc. now owns 1,544 shares of the company’s stock worth $33,000 after acquiring an additional 642 shares during the period. Finally, Salomon & Ludwin LLC acquired a new position in shares of Kenvue in the first quarter valued at approximately $33,000. Institutional investors own 97.64% of the company’s stock.

Kenvue Stock Performance

Shares of Kenvue stock opened at $23.02 on Friday. The company has a 50 day moving average of $20.92 and a 200-day moving average of $19.96. The company has a market cap of $44.08 billion, a PE ratio of 29.51, a price-to-earnings-growth ratio of 2.92 and a beta of 1.40. The company has a current ratio of 0.99, a quick ratio of 0.68 and a debt-to-equity ratio of 0.69. Kenvue Inc. has a 1-year low of $17.67 and a 1-year high of $23.55.

Kenvue (NYSE:KVUE) last issued its quarterly earnings results on Tuesday, August 6th. The company reported $0.32 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.28 by $0.04. Kenvue had a return on equity of 21.80% and a net margin of 7.23%. The company had revenue of $4 billion for the quarter, compared to analyst estimates of $3.93 billion. During the same quarter last year, the company posted $0.32 EPS. The company’s revenue for the quarter was down .3% compared to the same quarter last year. As a group, equities research analysts forecast that Kenvue Inc. will post 1.08 earnings per share for the current fiscal year.

Kenvue Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Wednesday, August 28th. Stockholders of record on Wednesday, August 14th were issued a $0.205 dividend. The ex-dividend date of this dividend was Wednesday, August 14th. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.56%. This is a boost from Kenvue’s previous quarterly dividend of $0.20. Kenvue’s dividend payout ratio is 105.13%.

Analyst Ratings Changes

Several analysts recently issued reports on the company. Deutsche Bank Aktiengesellschaft boosted their price target on Kenvue from $23.00 to $24.00 and gave the company a “buy” rating in a research note on Wednesday, August 7th. UBS Group upped their price target on shares of Kenvue from $20.00 to $22.00 and gave the company a “neutral” rating in a research note on Wednesday, August 7th. Citigroup lowered their price target on shares of Kenvue from $21.00 to $20.00 and set a “neutral” rating on the stock in a research report on Wednesday, July 10th. JPMorgan Chase & Co. increased their target price on shares of Kenvue from $22.00 to $24.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 7th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $24.00 target price on shares of Kenvue in a report on Wednesday, August 7th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and three have assigned a buy rating to the company. According to MarketBeat.com, Kenvue presently has a consensus rating of “Hold” and a consensus target price of $21.44.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.